Ferrari MD, Reuter U, Goadsby PJ, et al. - In patients with difficult-to-treat episodic migraine (EM) for whom 2–4 prior migraine preventives had failed, sustained efficacy of erenumab was observed over 112 weeks. Findings demonstrate safety and good tolerability of erenumab treatment, in-line with previous studies.

• A total of 240 LIBERTY study participants with EM for whom 2–4 prior preventatives had failed, who completed the placebo-controlled, double-blind treatment phase (DBTP) and entered an ongoing 3-year open-label extension phase (OLEP) with monthly erenumab 140 mg, were analyzed for outcomes.

• In OLEP, a total of 240/246 (97.6%) participants entered (118 continuing erenumab, 122 switching from placebo).

• At 112 weeks, ≥50% responder rate was estimated to be 57.2% (99/173).

• Among ≥50% responders at the end of the DBTP, 69.2% (36/52) continued to be responders at ≥50% and 42.3% (22/52) at >80% of visits.

• Among non-responders, 32.4% (60/185) converted to ≥50% responders in at least half the visits and 13.0% (24/185) converted to ≥50% responders in >80% of visits.

• Mean (SD) monthly migraine days showed a change, from baseline at 112 weeks, of −4.2 (5.0) days.

• Nasopharyngitis, influenza and back pain were documented to be the common adverse events (≥10%).